Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EncisionECIA 35 FCF Margin % is -11.45% as of Sep. 2025. GuruFocus rates ECIA with a GF Score™ of 35/100 and a GF Value™ of $0.34 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Encision ranks worse than 63.47% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Encision's Free Cash Flow for the
three
months ended in Sep. 2025 was $-0.18 Mil. Encision's Revenue for the
three
months ended in Sep. 2025 was $1.53 Mil. Therefore, Encision's FCF Margin % for the quarter that ended in Sep. 2025 was -11.45%.
The historical data trend for Encision's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Encision's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encision FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encision's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Encision's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Encision (ECIA) has a FCF Margin % of -11.45% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Encision and its competitors. According to the industry distribution chart, Encision ranks #516 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 63.5%.
Is Encision's FCF Margin % too high?
Encision's current FCF Margin % is -11.45%. Based on the distribution chart, Encision ranks #516 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Encision has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Encision's FCF Margin % compare to GCTK and YBGJ?
According to the Medical Devices & Instruments industry distribution chart, Encision ranks #516 out of 813 companies for FCF Margin %. This places Encision in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Encision and its competitors. Encision's current FCF Margin % is -11.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encision stock overvalued right now?
Based on GuruFocus' analysis, Encision (ECIA) is currently considered Possible Value Trap. The stock's GF Value™ is $0.34, compared to a current price of $0.19 — trading 44.1% below its estimated fair value. The current FCF Margin % is -11.45%. Encision's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Encision (ECIA), the current FCF Margin % is -11.45% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Encision (ECIA) Overvalued in 2026?
Based on GuruFocus' analysis, Encision stock appears to be undervalued.
The current stock price of $0.19 is trading 44.1% below its estimated GF Value™ of $0.34.
GuruFocus considers Encision to be Possible Value Trap.
Key valuation signals for ECIA:
FCF Margin %: -11.45%
GF Value™: $0.34 vs. price of $0.19 (44.1% below fair value)
No single metric tells the full story. See the ECIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provide surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities. Maximum revenue is generated from the product segment.
35GF Score
Get the complete analysis for ECIA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ECIA has been successfully added to your 
